Biblio Discovery — Demo Discovery Service

13 hasil untuk "Athanasios Tsianakas"

Menampilkan 1–13 · 0,88 detik · RSS

  1. Artikel Jurnal

    A Comparative Analysis of the Predictors, Extent and Impacts of Self-stigma in Patients with Psoriasis and Atopic Dermatitis

    Sophie Schlachter; Rachel Sommer; Matthias Augustin dkk.

    Acta Dermato-Venereologica, Vol. 103 · 2023 · Inggris · DOAJ Scopus

    The impact of dermatological diseases goes beyond symptoms and often includes psychosocial burden. Self-stigmatization plays a key role in this relationship and was compared in patients with psoriasis and atopic dermatitis to evaluate the validity of cross-disease stigmatization models. In total…

  2. Artikel Jurnal

    Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis

    Andreas Pinter; Athanasios Tsianakas; Adina Eichner dkk.

    Dermatology and Therapy, Vol. 14 No. 2 · 2024 · Inggris · DOAJ Scopus

    Abstract Introduction Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin inhibitor and is approved as an ointment…

  3. Artikel Jurnal

    Chronic Prurigo of Nodular Type: A Review

    Claudia Zeidler; Athanasios Tsianakas; Manuel Pereira dkk.

    Acta Dermato-Venereologica, Vol. 98 No. 2 · 2017 · Inggris · DOAJ Scopus

    Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules. PN evolves along with chronic pruritus in the context of diverse dermatological, systemic, neurological or psychiatric…

  4. Artikel Jurnal

    Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies

    Athanasios Tsianakas; Nina Magnolo; Afra Kempf dkk.

    Dermatology and Therapy, Vol. 16 No. 5 · 2026 · Inggris · DOAJ Scopus

    Abstract Introduction Tildrakizumab, an anti-IL-23p19 antibody, is registered for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Its effectiveness in specific patient subgroups—e.g. those with high body weight, high disease burden…

  5. Artikel Jurnal

    Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study

    Manuel P. Pereira; Pascale Salameh; Athanasios Tsianakas dkk.

    Dermatology and Therapy, Vol. 16 No. 9 · 2026 · Inggris · DOAJ Scopus

    Abstract Introduction Chronic inflammatory skin conditions significantly impact the quality of life (QoL) of those affected. Itch is a cardinal symptom in many of these conditions, contributing decisively to the burden of disease. This cross-sectional study explored how itch and related factors…

  6. Artikel Jurnal

    Exploratory Study of Intracutaneous Histamine Stimulation in Patient Populations with Chronic Pruritus

    Athanasios Tsianakas; Nadine Nippe; Christina Maria Hamper dkk.

    Acta Dermato-Venereologica, Vol. 99 No. 3 · 2018 · Inggris · DOAJ Scopus

    Chronic pruritus can be a diagnostic sign of an underlying disease. In the intracutaneous histamine test, histamine (one of the best-known inducers of pruritus) may cause different reaction patterns depending on the underlying disease. The aim of this study was to determine if an intracutaneous…

  7. Artikel Jurnal

    Introduction of a Specific Dermatological Rehabilitation Programme for Patients with Chronic Pruritus: A Pilot Study

    Sophia von Martial; Lisa Kok; Sonja Gründel dkk.

    Acta Dermato-Venereologica, Vol. 102 · 2022 · Inggris · DOAJ Scopus

    Chronic pruritus is a common symptom, associated with several severe medical conditions, great psychological burden, and reduced quality of life. It also poses socio-economic challenges concerning patients’ work loss and healthcare costs. In Germany, medical rehabilitation programmes represent an…

  8. Artikel Jurnal

    Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)

    Kristian Reich; Luca Bianchi; Abdallah Khemis dkk.

    Dermatology and Therapy, Vol. 14 No. 2 · 2024 · Inggris · DOAJ Scopus

    Abstract Introduction Despite improved treatment options for plaque psoriasis within the last decades, some patients still have an inadequate response to treatment. Direct clinical evaluation between therapies used after biologic failure could facilitate physicians’ choice of treatment. Methods…

  9. Artikel Jurnal

    Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

    Melinda J. Gooderham; Marjolein de Bruin-Weller; Stephan Weidinger dkk.

    Dermatology and Therapy, Vol. 14 No. 8 · 2024 · Inggris · DOAJ Scopus

    Abstract Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3 trials and a consistent, manageable safety…

  10. Artikel Jurnal

    Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

    Athanasios Tsianakas; Claudia Zeidler; Claudia Riepe dkk.

    Acta Dermato-Venereologica, Vol. 99 No. 4 · 2019 · Inggris · DOAJ Scopus

    The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive…

  11. Artikel Jurnal

    Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study

    Lina Renkhold; Manuel P. Pereira; Karin Loser dkk.

    Acta Dermato-Venereologica, Vol. 104 · 2024 · Inggris · DOAJ Scopus

    The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous neuroanatomy remained unknown. The primary objective of…

  12. Artikel Jurnal

    Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis

    Andreas Wollenberg; Jonathan I. Silverberg; Franz J. Legat dkk.

    Acta Dermato-Venereologica, Vol. 106 · 2026 · Inggris · DOAJ Scopus

    Nemolizumab with background topical therapy (corticosteroids±calcineurin inhibitors) significantly improved skin lesions, itch and sleep in two global phase 3 trials (ARCADIA 1&2) in adolescents and adults with moderate-to-severe atopic dermatitis through week (W)16. Efficacy and safety of…